Oct 7 Mylan NV said it agreed to a $465
million settlement with the U.S. Department of Justice related
to the manner in which it had improperly classified its EpiPen
emergency allergy treatment to pay lower rebates to state health
Mylan will record a pre-tax charge of about $465 million in
the quarter ended Sept. 30 as a result of the settlement, it
said on Friday.
The company also lowered its full-year adjusted profit
forecast to $4.70-$4.90 per share from $4.85-$5.15.
(Reporting by Narottam Medhora in Bengaluru; Editing by Don